Skip to main content
. 2011 Mar;336(3):916–924. doi: 10.1124/jpet.110.173740

Fig. 5.

Fig. 5.

GABAB receptors were not involved in KRS-5Me-4-OCF3-evoked inhibition. A, original recording from an MC during KRS-5Me-4-OCF3 application in the ACSF condition and in the presence of GABABR antagonist CGP55845. The upper trace (i) illustrates the effect of KRS-5Me-4-OCF3 on spiking of an MC and the effect of adding CGP55845. The upper trace is shown at an extended time scale in the middle (ii) and lower trace (iii). B, the normalized results showed the persistence of KRS-5Me-4-OCF3-evoked inhibitory effects on spiking of MCs in the presence of the GABABR antagonist CGP55845 (10 μM) and the GABABR agonist (R)-baclofen (50 μM). *, p < 0.05; ***, p < 0.001. The data for the effect of KRS-5Me-4-OCF3 on spiking of MCs were normalized with respect to ACSF, CGP88545, or baclofen alone.